title: Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study.
abstract: OBJECTIVE
  We used a new differential display method, the annealing control primer (ACP) system, to analyse the differentially expressed genes in mucinous ovarian tumours. To verify the corresponding target gene, immunohistochemical staining was performed on various epithelial tumours of the ovary.
  
  
  RESULTS
  The ACP-based reverse transcriptase-polymerase chain reaction revealed that 21 genes were upregulated in the mucinous ovarian adenoma and 14 genes were upregulated in the mucinous ovarian carcinoma. Among them, we selected one upregulated gene, the Mac-2 binding protein (Mac-2 BP), and verified the expression of the Mac-2 BP and its ligand, galectin-3, in a variety of epithelial ovarian tumours by immunohistochemistry. Positive expression of the Mac-2 BP was significantly higher in the mucinous ovarian tumours compared to the other epithelial tumours. Mac-2 BP expression was significantly increased in the borderline and malignant tumours compared to the benign tumours. Galectin-3 expression was more frequent in clear cell carcinomas, serous tumours and mucinous tumours than in endometrioid and transitional tumours. However, there were no differences in galectin-3 expression in comparisons among benign, borderline and malignant mucinous and serous tumours.
  
  
  CONCLUSIONS
  These data indicate that the Mac-2 BP may play a role in the development and progression of mucinous ovarian tumours.
authors.affiliation: Department of Pathology, Medical College, Korea University, Seoul, Korea.
authors.forename: Ju-Han
authors.initials: JH
authors.lastname: Lee
authors.forename: Xianglan
authors.initials: X
authors.lastname: Zhang
authors.forename: Bong Kyung
authors.initials: BK
authors.lastname: Shin
authors.forename: Eung Seok
authors.initials: ES
authors.lastname: Lee
authors.forename: Insun
authors.initials: I
authors.lastname: Kim
mesh_terms: D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D018282:Cystadenocarcinoma, Mucinous / Q000235:genetics / Q000378:metabolism*; D017931:DNA Primers; D005260:Female; D037502:Galectin 3 / Q000096:biosynthesis* / Q000235:genetics; D015870:Gene Expression; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D046888:Tissue Array Analysis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017931:DNA Primers; D037502:Galectin 3; D008562:Membrane Glycoproteins; C114782:TAA90K protein, human